ciprofloxacin has been researched along with Acute Liver Injury, Drug-Induced in 29 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Neutropenia and thrombocytopenia associated with cefoxitin developed in 33 (51%) and 4 (6%) patients, respectively." | 3.75 | Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. ( Jeon, K; Kim, BJ; Kim, CK; Koh, WJ; Kook, YH; Kwon, OJ; Lee, NY; Lee, SH; Park, YK, 2009) |
| "Twenty-five patients who had extensive pulmonary tuberculosis and hepatitis induced by antituberculosis drugs were treated with ciprofloxacin together with other relatively non-hepatotoxic drugs, either during the interim phase awaiting recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | 2.68 | Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. ( Chan, CY; Chau, CH; Cheng, AF; Cheung, SW; Lee, J; Wong, CF; Wong, PC; Yew, WW, 1995) |
| "Ciprofloxacin is a common, broad spectrum antibacterial agent; however, evidence is accumulating that ciprofloxacin may cause liver damage." | 1.43 | Quercetin protection against ciprofloxacin induced liver damage in rats. ( Cetin, A; Dogan, Z; Elbe, H; Taslidere, E; Turkoz, Y; Vardi, N, 2016) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Ciprofloxacin is a fluoroquinolone antibiotic that has a relatively low rate of occurence of adverse side effects." | 1.37 | Unexpected severe hepatotoxicity of ciprofloxacine: two case reports. ( Alan, C; Ersay, AR; Ertung, Y; Koçoğlu, H; Kurt, HA, 2011) |
| "Surveillance of ciprofloxacin usage in a pediatric population failed to demonstrate serious or unusually high rates of any adverse events, including joint toxicity." | 1.30 | Ciprofloxacin safety in a pediatric population. ( Jick, S, 1997) |
| "It is suggested that ciprofloxacin can cause severe hepatic injury and that healthcare providers should be aware of this possible adverse drug reaction." | 1.29 | Suspected ciprofloxacin-induced hepatotoxicity. ( Côté, J; Davies, C; Villeneuve, JP, 1995) |
| "Ciprofloxacin was started on postoperative day 13 for treatment of a urinary tract infection." | 1.28 | Fulminant hepatic failure possibly related to ciprofloxacin. ( Grassmick, BK; Lehr, VT; Sundareson, AS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (20.69) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Gu, S | 1 |
| Rajendiran, G | 1 |
| Forest, K | 1 |
| Tran, TC | 1 |
| Denny, JC | 1 |
| Larson, EA | 1 |
| Wilke, RA | 1 |
| Amorha, KC | 1 |
| Ugwuowo, OB | 1 |
| Ayogu, EE | 1 |
| Nduka, SO | 1 |
| Okonta, MJ | 1 |
| Radovanovic, M | 1 |
| Dushenkovska, T | 1 |
| Cvorovic, I | 1 |
| Radovanovic, N | 1 |
| Ramasamy, V | 1 |
| Milosavljevic, K | 1 |
| Surla, J | 1 |
| Jecmenica, M | 1 |
| Radulovic, M | 1 |
| Milovanovic, T | 1 |
| Dumic, I | 1 |
| Alshammari, TM | 1 |
| Larrat, EP | 1 |
| Morrill, HJ | 1 |
| Caffrey, AR | 1 |
| Quilliam, BJ | 1 |
| LaPlante, KL | 1 |
| Taslidere, E | 1 |
| Dogan, Z | 1 |
| Elbe, H | 1 |
| Vardi, N | 1 |
| Cetin, A | 1 |
| Turkoz, Y | 1 |
| Moreno, L | 1 |
| Sánchez-Delgado, J | 1 |
| Vergara, M | 1 |
| Casas, M | 1 |
| Miquel, M | 1 |
| Dalmau, B | 1 |
| Bhagirath, KM | 1 |
| Jeon, K | 1 |
| Kwon, OJ | 1 |
| Lee, NY | 1 |
| Kim, BJ | 1 |
| Kook, YH | 1 |
| Lee, SH | 1 |
| Park, YK | 1 |
| Kim, CK | 1 |
| Koh, WJ | 1 |
| Alan, C | 1 |
| Koçoğlu, H | 1 |
| Ersay, AR | 1 |
| Ertung, Y | 1 |
| Kurt, HA | 1 |
| Hauben, M | 1 |
| Bataille, L | 1 |
| Rahier, J | 1 |
| Geubel, A | 1 |
| Zaidi, SA | 1 |
| Marra, F | 1 |
| Cox, VC | 1 |
| FitzGerald, JM | 1 |
| Moadebi, S | 1 |
| Elwood, RK | 1 |
| Yew, WW | 1 |
| Chau, CH | 1 |
| Wong, PC | 1 |
| Lee, J | 1 |
| Wong, CF | 1 |
| Cheung, SW | 1 |
| Chan, CY | 1 |
| Cheng, AF | 1 |
| Villeneuve, JP | 1 |
| Davies, C | 1 |
| Côté, J | 1 |
| Hautekeete, ML | 1 |
| Kockx, MM | 1 |
| Naegels, S | 1 |
| Holvoet, JK | 1 |
| Hubens, H | 1 |
| Kloppel, G | 1 |
| Jick, S | 1 |
| Contreras, MA | 1 |
| Luna, R | 1 |
| Mulero, J | 1 |
| Andreu, JL | 1 |
| Clark, DW | 1 |
| Layton, D | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Shakir, SA | 1 |
| Grassmick, BK | 1 |
| Lehr, VT | 1 |
| Sundareson, AS | 1 |
| Chiu, J | 1 |
| Nussbaum, J | 1 |
| Bozzette, S | 1 |
| Tilles, JG | 1 |
| Young, LS | 1 |
| Leedom, J | 1 |
| Heseltine, PN | 1 |
| McCutchan, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury[NCT03266146] | Phase 1/Phase 2 | 90 participants (Actual) | Interventional | 2017-09-02 | Completed | ||
| A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury[NCT02651350] | Phase 1/Phase 2 | 80 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ciprofloxacin and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Chemical and Drug Induced Liver Injury; Ciprofloxac | 2018 |
1 trial available for ciprofloxacin and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cipro | 1995 |
26 other studies available for ciprofloxacin and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Drug-Induced Liver Injury with Commonly Used Antibiotics in the All of Us Research Program.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cep | 2023 |
Evaluation of the hepatic effect of concomitant administration of ciprofloxacin and some antimalarial drugs in Plasmodium berghei infected mice: An in vivo study.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Chemical and Drug Induced Liver Injury; Ciprofloxacin | 2018 |
Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Chemical and Dr | 2014 |
Quercetin protection against ciprofloxacin induced liver damage in rats.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Cytoprotection; Diseas | 2016 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
Recurrent drug-induced liver injury (DILI) with ciprofloxacin and amoxicillin/clavulanic.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chemical and Drug Induced Live | 2015 |
A case report of highly suspected ciprofloxacin-induced hepatotoxicity.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Ciproflo | 2008 |
Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefoxitin; Chemical and Drug Induced | 2009 |
Unexpected severe hepatotoxicity of ciprofloxacine: two case reports.
Topics: Alanine Transaminase; Anti-Infective Agents; Aspartate Aminotransferases; Chemical and Drug Induced | 2011 |
Re: Lasso-de-la-Vega et al. gabapentin as a probable cause of hepatotoxicity and eosinophilia.
Topics: Acetates; Amines; Analgesics; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Ciprofl | 2002 |
Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease.
Topics: Anti-Infective Agents; Bile Ducts; Chemical and Drug Induced Liver Injury; Cholestasis; Chronic Dise | 2002 |
Hepatitis associated with amoxicillin/clavulanic acid and/or ciprofloxacin.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Amoxicillin-Potassium Clavulana | 2003 |
Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ciprofl | 2004 |
Suspected ciprofloxacin-induced hepatotoxicity.
Topics: Administration, Oral; Adult; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Endometritis; Fe | 1995 |
Cholestatic hepatitis related to quinolones: a report of two cases.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Cholestasis; | 1995 |
Ciprofloxacin safety in a pediatric population.
Topics: Adolescent; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1997 |
Severe ciprofloxacin-induced acute hepatitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Ciprofloxacin; | 2001 |
Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database.
Topics: Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Ci | 2001 |
Fulminant hepatic failure possibly related to ciprofloxacin.
Topics: Administration, Oral; Aged; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Hip Prosthesis; H | 1992 |
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Amikacin; Chemical and Drug Induced Liver | 1990 |